Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Windpessl, M; Gauckler, P; Zitt, E; Lhotta, K; Ay, C; Eller, K; Odler, B; Neumann, I; Rudnicki, M; Kronbichler, A; Säemann, MD.
[General recommendations for the management of glomerular diseases-2023].
Wien Klin Wochenschr. 2023; 135(Suppl 5): 696-704. Doi: 10.1007/s00508-023-02265-6 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Eller Kathrin

Odler Balazs

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Glomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreover, practical recommendations for the prevention of thromboembolism in states of nephrosis and for the prophylaxis of Pneumcystic jirovecii pneumonia are provided.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Nephrotic Syndrome - administration & dosage

Cyclophosphamide - administration & dosage

Thromboembolism - administration & dosage

Find related publications in this database (Keywords)

Thromboembolism

Nephrotic syndrome

Rituximab

Cyclophophamide

Pneumocystis jirovecii

© Med Uni Graz • Imprint